Astellas UK’s suspension from membership of the ABPI extended
Astellas UK was suspended from membership of the Association of the British Pharmaceutical Industry (ABPI) with effect from 24 June 2016. This has been extended for a further 12 months.
Press Release 23 June 2017
The original suspension was in connection with a serious matter which came to light during the PMCPA consideration of two complaints and, as a consequence, Astellas UK and Astellas Europe were reported to the ABPI Board.
In addition, three cases arising from voluntary admissions made between October 2016 and February 2017, Case AUTH/2883/10/16 and Cases AUTH/2939/2/17 and AUTH/2940/2/17, were reported to the Code of Practice Appeal Board which reported them to the ABPI Board.
Both companies have been audited, re-audited and will be re-audited in October 2017.
Full details can be found in the case reports, Case AUTH/2780/7/15 and AUTH/2747/1/15, Case AUTH/2883/10/16 and Cases AUTH/2939/2/17 and AUTH/2940/2/17.
The ABPI issued a press release which has since been updated here.